Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06721065 · ClinicalTrials.gov registry record · NA

A Study of Language Interpretation Solutions for People With Breast Cancer

A NA study of Breast Cancer and Breast Cancer Stage II, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
NA
Development phase
700
Enrollment target
8
Study locations

NCT06721065 is a NA study of Breast Cancer and Breast Cancer Stage II that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 700 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (75% lower). The trial reports 8 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06721065, a NA study of Breast Cancer and Breast Cancer Stage II, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
NA
Development phase
700 participants
Enrollment target
8
Study locations

Study Summary

The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/RSMI (Arm 1), versus Remote Consecutive Medical Interpreting/RCMI (Arm 2) and versus Remote Consecutive Video Medical Interpreting/RCVI (Arm 3) in breast cancer outpatient clinical encounters with Spanish- and Mandarin-speaking patients with Limited English Proficiency/LEP (Stages II and III disease) and English- speaking providers (who do not speak Spanish/Mandarin). In Phase 2, there will be a sequential mixed-methods explanatory, multi-stakeholder process evaluation to gather implementation potential data.

Interventions

  • OTHER Remote Simultaneous Medical Interpreting/RSMI
  • OTHER Remote Consecutive Medical Interpreting/RCMI
  • OTHER Remote Consecutive Video Medical Interpreting/RCVI

Study Locations (8)

New York

  • Memorial Sloan Kettering Suffolk- Commack (Consent Only) - Commack
  • Memorial Sloan Kettering Westchester (Consent Only) - Harrison
  • Memorial Sloan Kettering at Ralph Lauren Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Consent Only) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Consent Only) - Middletown
  • Memorial Sloan Kettering Bergen (Consent Only) - Montvale

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2024-12-02
Est. Completion 2029-12-02
Phase NA

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT06721065

The ClinicalTrials.gov registry entry for NCT06721065 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Remote Simultaneous Medical Interpreting/RSMI is the first listed.

NCT06721065 reports 8 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06721065 about?

NCT06721065 is a clinical study titled "A Study of Language Interpretation Solutions for People With Breast Cancer". The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/RSMI (Arm 1), versus Remote Consecutive Medical Interpreting/RCMI (Arm 2) and versus Remote Consecutive Video Medical Interpreting/RCVI (Arm ...

What is the current status of trial NCT06721065?

This trial is currently recruiting. It is a NA study. The enrollment target is 700 participants. The study started on 2024-12-02. Estimated completion is 2029-12-02.

What conditions does trial NCT06721065 study?

This clinical trial studies the following conditions: Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III.

What interventions are being tested in trial NCT06721065?

The interventions under investigation include: Remote Simultaneous Medical Interpreting/RSMI (OTHER), Remote Consecutive Medical Interpreting/RCMI (OTHER), Remote Consecutive Video Medical Interpreting/RCVI (OTHER).

Who is sponsoring clinical trial NCT06721065?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06721065 being conducted?

This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.